(PRME) Prime Medicine, Common Stock - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 610m USD | Total Return: 89.9% in 12m
Stock
Gene Editing, Genetic Therapies, Biotechnology
Total Rating 42
Risk 69
Buy Signal -1.19
Market Cap:
610m
Avg Trading Vol: 8.54M USD
Avg Trading Vol: 8.54M USD
ATR:
9.17%
Peers RS (IBD): 34.3
Peers RS (IBD): 34.3
Risk 5d forecast
Volatility89.3%
Rel. Tail Risk-7.26%
Reward TTM
Sharpe Ratio1.00
Alpha31.03
Character TTM
Beta2.801
Beta Downside3.299
Drawdowns 3y
Max DD93.26%
CAGR/Max DD-0.36
Risks
Technicals:
volatile
Description: PRME Prime Medicine, Common Stock
Prime Medicine, Inc. (PRME) is a biotechnology company focused on gene editing therapies in the United States. The biotechnology sector is characterized by extensive research and development phases and regulatory approval processes.
The company utilizes its proprietary Prime Editing technology, which employs modified Cas domains and an RT domain to directly insert edited DNA sequences without creating double-stranded breaks. This approach aims to provide precise genetic modifications.
PRME is collaborating with Cimeio Therapeutics to develop therapies for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. This demonstrates a common business model in biotechnology: strategic partnerships to advance drug development.
For more detailed financial and operational data, ValueRay offers comprehensive company profiles.
- Prime Editing technology development dictates future revenue potential
- Clinical trial results for genetic therapies impact stock valuation
- Regulatory approvals for gene editing treatments are critical
- Collaboration success with Cimeio Therapeutics expands market reach
- Research and development expenses influence profitability
Piotroski VR‑10 (Strict, 0-10)
0.5
| Net Income: -201.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.49 > 0.02 and ΔFCF/TA -5.00 > 1.0 |
| NWC/Revenue: 3.11k% < 20% (prev 426.7%; Δ 2.68k% < -1%) |
| CFO/TA -0.47 > 3% & CFO -162.6m > Net Income -201.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (148.8m) vs 12m ago 25.43% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 1.45% > 50% (prev 13.70%; Δ -12.25% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z''
-14.12
| A: 0.42 (Total Current Assets 181.3m - Total Current Liabilities 37.4m) / Total Assets 342.7m |
| B: -2.59 (Retained Earnings -888.4m / Total Assets 342.7m) |
| C: -0.63 (EBIT TTM -201.1m / Avg Total Assets 320.1m) |
| D: -4.00 (Book Value of Equity -888.3m / Total Liabilities 221.9m) |
| Altman-Z'' Score: -14.12 = D |
Beneish M
| DSRI: none (Receivables none/none, Revenue 4.63m/40.8m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.91 (AQ_t 0.04 / AQ_t-1 0.05) |
| SGI: 0.11 (Revenue 4.63m / 40.8m) |
| TATA: -0.11 (NI -201.1m - CFO -162.6m) / TA 342.7m) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of PRME shares?
As of April 02, 2026, the stock is trading at USD 3.48 with a total of 2,032,780 shares traded.
Over the past week, the price has changed by -6.61%, over one month by -27.25%, over three months by -3.97% and over the past year by +89.92%.
Over the past week, the price has changed by -6.61%, over one month by -27.25%, over three months by -3.97% and over the past year by +89.92%.
Is PRME a buy, sell or hold?
Prime Medicine, Common Stock has received a consensus analysts rating of 4.17.
Therefore, it is recommended to buy PRME.
- StrongBuy: 6
- Buy: 2
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PRME price?
| ISSUER | TARGET | UP/DOWN |
|---|---|---|
| Wallstreet Target Price | 6.9 | 98.9% |
| Analysts Target Price | 6.9 | 98.9% |
PRME Fundamental Data Overview
as of 29 March 2026
P/S = 131.7501 P/B = 5.2582
Revenue TTM = 4.63m USD
EBIT TTM = -201.1m USD
EBITDA TTM = -195.8m USD
Long Term Debt = 116.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 8.14m USD (from shortTermDebt, last quarter)
Debt = 116.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 53.4m USD (from netDebt column, last quarter)
Enterprise Value = 549.0m USD (610.3m + Debt 116.4m - CCE 177.7m)
Interest Coverage Ratio = unknown (Ebit TTM -201.1m / Interest Expense TTM 0.0)
EV/FCF = -3.29x (Enterprise Value 549.0m / FCF TTM -167.1m)
FCF Yield = -30.44% (FCF TTM -167.1m / Enterprise Value 549.0m)
FCF Margin = -3.61k% (FCF TTM -167.1m / Revenue TTM 4.63m)
Net Margin = -4.34k% (Net Income TTM -201.1m / Revenue TTM 4.63m)
Gross Margin = unknown ((Revenue TTM 4.63m - Cost of Revenue TTM 49.4m) / Revenue TTM)
Tobins Q-Ratio = 1.60 (Enterprise Value 549.0m / Total Assets 342.7m)
Interest Expense / Debt = 0.37% (Interest Expense 434k / Debt 116.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -158.9m (EBIT -201.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.84 (Total Current Assets 181.3m / Total Current Liabilities 37.4m)
Debt / Equity = 0.96 (Debt 116.4m / totalStockholderEquity, last quarter 120.9m)
Debt / EBITDA = -0.27 (negative EBITDA) (Net Debt 53.4m / EBITDA -195.8m)
Debt / FCF = -0.32 (negative FCF - burning cash) (Net Debt 53.4m / FCF TTM -167.1m)
Total Stockholder Equity = 112.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -62.83% (Net Income -201.1m / Total Assets 342.7m)
RoE = -178.6% (Net Income TTM -201.1m / Total Stockholder Equity 112.6m)
RoCE = -87.82% (EBIT -201.1m / Capital Employed (Equity 112.6m + L.T.Debt 116.4m))
RoIC = -141.1% (out of range, set to none) (NOPAT -158.9m / Invested Capital 112.6m)
WACC = 13.35% (E(610.3m)/V(726.7m) * Re(15.84%) + D(116.4m)/V(726.7m) * Rd(0.37%) * (1-Tc(0.21)))
Discount Rate = 15.84% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 27.96%
[DCF] Fair Price = unknown (Cash Flow -167.1m)
EPS Correlation: 31.15 | EPS CAGR: 0.0% | SUE: 0.16 | # QB: 0
Revenue Correlation: 23.32 | Revenue CAGR: 97.06% | SUE: -0.07 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.23 | Chg7d=-0.001 | Chg30d=+0.014 | Revisions Net=+1 | Analysts=10
EPS current Year (2026-12-31): EPS=-0.93 | Chg7d=+0.002 | Chg30d=-0.026 | Revisions Net=-3 | Growth EPS=+31.4% | Growth Revenue=+188.5%
EPS next Year (2027-12-31): EPS=-0.81 | Chg7d=+0.000 | Chg30d=-0.003 | Revisions Net=-3 | Growth EPS=+12.3% | Growth Revenue=+47.7%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)